Drug intelligence / Profile preview

KOfactor2

Development stage: Preclinical
Lead developer: KoDiscovery and New G Lab Pharma
Administration: Oral

Overview

KOfactor2 is a natural supplement and nutraceutical developed by NewG Lab Pharma in collaboration with KoDiscovery. It is part of a specialized product line designed to target cancer metabolism, specifically focusing on the Warburg Effect (aerobic glycolysis in cancer cells). While its sister product, KOfactor1, is known to contain a combination of luteolin, rutin, and EGCG, the specific active ingredients and formulation of KOfactor2 have not been publicly disclosed. The product is intended to support the metabolic health and quality of life of cancer patients by modulating signaling pathways involved in tumor growth and whole-body metabolism.

Brand names: KOfactor2KOfactor-2KOfactor 2
Other names: KOfactor 2KOfactor2KOfactor-2

Beyond the preview

Go deeper on KOfactor2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KOfactor2.

Explore the full profile